↓ Skip to main content

Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study

Overview of attention for article published in Journal of Translational Medicine, March 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
policy
1 policy source
twitter
60 X users
patent
1 patent
facebook
12 Facebook pages
wikipedia
3 Wikipedia pages
googleplus
3 Google+ users
reddit
2 Redditors

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
82 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Activin B is a novel biomarker for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) diagnosis: a cross sectional study
Published in
Journal of Translational Medicine, March 2017
DOI 10.1186/s12967-017-1161-4
Pubmed ID
Authors

Brett A. Lidbury, Badia Kita, Donald P. Lewis, Susan Hayward, Helen Ludlow, Mark P. Hedger, David M. de Kretser

Abstract

Investigations of activin family proteins as serum biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). CFS/ME is a disease with complex, wide-ranging symptoms, featuring persistent fatigue of 6 months or longer, particularly post exertion. No definitive biomarkers are available. A cross-sectional, observational study of CFS/ME patients fulfilling the 2003 Canadian Consensus Criteria, in parallel with healthy non-fatigued controls, was conducted. Comparisons with a previously defined activin reference population were also performed. For the total study cohort the age range was 18-65 years with a female: male participant ratio of greater than 3:1. All participants were assessed via a primary care community clinic. Blood samples were collected for pathology testing after physical examination and orthostatic intolerance assessment. Cytokines, activin A, activin B and follistatin were also measured in sera from these samples. All data were compared between the CFS/ME and control cohorts, with the activins and follistatin also compared with previously defined reference intervals. Serum activin B levels for CFS/ME participants were significantly elevated when compared to the study controls, as well as the established reference interval. Serum activin A and follistatin were within their normal ranges. All routine and special pathology markers were within the normal laboratory reference intervals for the total study cohort, with no significant differences detected between CFS/ME and control groups. Also, no significant differences were detected for IL-2, IL-4, IL-6, IL-10, IL-17A, TNF or IFN-gamma. Elevated activin B levels together with normal activin A levels identified patients with the diagnostic symptoms of CFS/ME, thus providing a novel serum based test. The activins have multiple physiological roles and capture the diverse array of symptoms experienced by CFS/ME patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 60 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 82 100%

Demographic breakdown

Readers by professional status Count As %
Other 10 12%
Student > Bachelor 10 12%
Researcher 9 11%
Student > Doctoral Student 7 9%
Student > Ph. D. Student 6 7%
Other 23 28%
Unknown 17 21%
Readers by discipline Count As %
Medicine and Dentistry 17 21%
Biochemistry, Genetics and Molecular Biology 6 7%
Nursing and Health Professions 6 7%
Neuroscience 6 7%
Agricultural and Biological Sciences 4 5%
Other 19 23%
Unknown 24 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 78. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 January 2024.
All research outputs
#541,656
of 25,332,933 outputs
Outputs from Journal of Translational Medicine
#114
of 4,613 outputs
Outputs of similar age
#11,373
of 314,746 outputs
Outputs of similar age from Journal of Translational Medicine
#5
of 66 outputs
Altmetric has tracked 25,332,933 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,613 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,746 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.